相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients With Hepatitis C Virus Infection
Thomas Reiberger et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis
Martin Hennenberg et al.
LABORATORY INVESTIGATION (2011)
Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
Romain Coriat et al.
PLOS ONE (2011)
Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?
Florian Hucke et al.
WIENER KLINISCHE WOCHENSCHRIFT (2011)
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma
Markus Peck-Radosavljevic et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis
Yan Wang et al.
JOURNAL OF HEPATOLOGY (2010)
Acute Hepatitis in a Patient With Cirrhosis and Hepatocellular Carcinoma Treated With Sorafenib
Lucia Llanos et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis
M. Hennenberg et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Beneficial Effects of Sorafenib on Splanchnic, Intrahepatic, and Portocollateral Circulations in Portal Hypertensive and Cirrhotic Rats
Marc Mejias et al.
HEPATOLOGY (2009)
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats
Thomas Reiberger et al.
JOURNAL OF HEPATOLOGY (2009)
Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
Matthias Pinter et al.
ONCOLOGIST (2009)
Review article: the modern management of portal hypertension - primary and secondary prophylaxis of variceal bleeding in cirrhotic patients
J. C. Garcia-Pagan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Sorafenib-Induced Liver Failure
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Mechanisms of extrahepatic vasodilation in portal hypertension
M. Hennenberg et al.
GUT (2008)
Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury
Erawan Borkham-Kamphorst et al.
LABORATORY INVESTIGATION (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Measurement of portal pressure and its role in the management of chronic liver disease
Jaime Bosch et al.
SEMINARS IN LIVER DISEASE (2006)
Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis
Q. Zhou et al.
GUT (2006)
The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule
Y Iwakiri et al.
HEPATOLOGY (2006)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells
M Fukushima et al.
LIVER INTERNATIONAL (2005)
Austrian consensus on the definition and treatment of portal hypertension and its complications
M Peck-Radosavljevic et al.
ENDOSCOPY (2005)
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats
M Fernandez et al.
JOURNAL OF HEPATOLOGY (2005)
Increased hepatic resistance -: A new target in the pharmacologic therapy of portal hypertension
M Hernández-Guerra et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2005)
Portal hypertension - From bedside to bench
RJ Groszmann et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2005)
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice
M Fernandez et al.
GASTROENTEROLOGY (2004)
The hepatic venous pressure gradient: Anything worth doing should be done right
RJ Groszmann et al.
HEPATOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells
H Ikeda et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2003)
Vascular mediators in the injured liver
DC Rockey
HEPATOLOGY (2003)
Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis
R Bañares et al.
HEPATOLOGY (2002)
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference
J Bruix et al.
JOURNAL OF HEPATOLOGY (2001)
Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension
A Escorsell et al.
HEPATOLOGY (2000)
Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
SL Friedman
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Complications of cirrhosis. I. Portal hypertension
J Bosch et al.
JOURNAL OF HEPATOLOGY (2000)
分享论文
